ACME UNITED CORP - 10-Q Summary (Period Ended June 30, 1995)
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for ACME UNITED CORPORATION for the period ended June 30, 1995. The company operates in consumer and medical product sectors with significant foreign operations, particularly in Germany and the UK. The report covers the three and six months ended June 30, 1995, compared to the same periods in 1994.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1995 | Six Months Ended June 30, 1994 |
|---|---|---|
| Net Sales | $27,367,286 | $26,721,194 |
| Net Income | $173,684 | $66,097 |
| Gross Profit Margin | 29% | 27% |
| Operating Cash Flow | ($2,736,853) | ($2,148,090) |
| Capital Expenditures | $538,014 | $617,693 |
| Total Debt (Current + Long Term) | $22,195,895 | $18,387,659 |
| Working Capital | $23,413,000 | $21,035,000 |
| Current Ratio | 3.02 | 3.23 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 2% ($646,000) for the six-month period. U.S. consumer operations drove a 11% increase, while medical operations declined 2% due to lower wound care product volumes.
- Profitability: Net income improved significantly to $173,684 from $66,097 in the prior year. Gross margins expanded to 29% from 27%, aided by lower manufacturing costs and price increases in consumer goods, despite competitive pressures in medical products.
- Debt and Interest: Total debt increased by approximately $3.8 million, leading to a $222,000 increase in interest expense due to higher average borrowings and rates on the U.S. revolving line of credit.
- Cash Flow: Operating cash flow remained negative at ($2.74 million), primarily driven by a $2.6 million increase in accounts receivable and a $1.25 million increase in inventory.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects total capital expenditures for 1995 to be approximately $1,200,000.
- Liquidity: The company maintains a $13,000,000 U.S. revolving line of credit expiring in March 1997. Management believes current cash balances and financing arrangements are sufficient to meet 1995 commitments.
- Foreign Currency: Foreign sales were positively impacted by approximately $900,000 in translation gains due to the strength of the German mark and British pound. Conversely, these currency fluctuations increased SG&A expenses.
- Risks: The filing notes that results for the first half of the year are not necessarily indicative of full-year results. Competitive market conditions in the medical sector continue to limit the ability to pass on cost increases.
Investor Verification Checklist
- Verify the sustainability of the 29% gross margin given the competitive pressure in the medical segment.
- Monitor the trend in accounts receivable and inventory, which are the primary drivers of negative operating cash flow.
- Confirm the status of the $13 million U.S. revolving credit line and foreign overdraft arrangements as they approach maturity.
- Assess the impact of foreign currency fluctuations on future earnings, given the significant translation effects noted in the current period.